FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of July 1999
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F X Form 40 - F
------- -------
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes No X
------- -------
This Form 6-K consists of:
A press release issued by Vasogen Inc. on July 6, 1999, titled:
"Donald A. Grilli Appointed To Vasogen's Board of Directors"
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /s/ Christopher Waddick
---------------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: July 7, 1999
<PAGE>
Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive, Suite 10
Mississauga, ON, Canada L5L 4M1 Trevor Burns
tel (905)569-2265 fax (905)569-9231 Investor Relations
http://www.vasogen.com tel (905) 569-9065
e-mail [email protected]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
DONALD A. GRILLI APPOINTED TO VASOGEN'S BOARD OF DIRECTORS
TORONTO, Ontario, (July 6th, 1999) -- Vasogen Inc. (ME:VAS; OTCBB:VSOGF) is
pleased to announce, subject to regulatory approval, the appointment of Donald
A. Grilli of Boston, Massachusetts, to its Board of Directors.
During his more than thirty years with Johnson & Johnson (J&J), a diversified
health care product company, Mr. Grilli held senior executive positions across
seven J&J companies. Most recently, as President of Johnson & Johnson
Professional, Inc., his leadership resulted in a three-fold increase in revenues
to over $1 billion and positioned the company as the worldwide market leader in
the orthopedic and neurosurgical sectors.
Mr. Grilli also served as Executive Vice-President of J&J's Surgikos, a $500
million manufacturer of disposable products for the operating room, as Executive
Vice-President of Sales and Marketing for J&J's Ultrasound Division, and in
various executive roles with J&J's Technicare, a global high tech manufacturer
of CT Scanners, MRI units, and nuclear equipment.
Dr. William Cochrane, Vasogen's Chairman stated: "We are delighted that an
individual as accomplished as Donald Grilli has chosen to join our Board. With
his extensive experience in the medical device industry, Don brings impressive
strength in the areas of operations, marketing and licensing."
Vasogen is developing proprietary immune modulation therapies to advance
the treatment of cardiovascular, autoimmune and related
inflammatory diseases. These therapies are designed
to target fundamental disease-causing events,
providing safe, effective treatment.
